Why Is Mirum Pharmaceuticals Stock Gaining Monday?
Mirum stock surges after LIVMARLI wins Phase 3 trial, showing significant itch and bile acid reduction in biliary atresia patients.
Share
Why It Matters
Mirum's new medicine passed a big test for a serious liver disease. When a company's medicine works well in testing, people feel more hopeful about the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.